str, you are coming the drama queen on this board. NONE of the analysts have anything baked in their numbers for any significant growth in the injectable. neither does the company. The $110M for 2014 and $150-$160M for 2015 is NOT based on the injectable. That would all be gravy. It's a very minor piece of the business currently and a very minor piece of the forecasted revenue for 2014 and 2015. The stock price does NOT assume that the injectable will stay on the market. In fact, the company could get out of the injectable entirely and still do hundreds of millions in revenue by 2016-2017
What you are missing is this. The company is negotiating in conjunction with the BLA process, to be allowed to continue selling the injectable during the BLA process given its perfect safety record with hundreds of thousands of injections. Not one negative event. If MDXG can get this done, it doesn't really matter how long the BLA takes, probably until 2016 as they would be able to sell. In fact, right now there are no marketing efforts at all by the company so if a deal is struck, the company should be able to get back to marketing it.
REALLY encouraging numbers for the week of 5/30. Most drugs I follow down 10-17% because it was a 4 day work week with memorial day so its normal for numbers to take a big hit BUT for week of 5/30, TRX 249 vs 204 for prior week, UP 22%. NRx 174 vs 143 prior week, up 22%. Encouraging.
Just read thru today's analyst notes on MDT. No one seems to think a bid is likely. However, of note in Wells Fargo's note "SNN would provide entry into orthopedics, sports medicine and wound care which are new markets for MDT. Orthopedic and wound care management represent gaping holes in their portfolio."
Didn't the shorts day he would lose? LOL. Too bad the SEC can't be sanctioned for bringing a bogus suit
of note in the slide deck, they have launched in the prostatectomy and craniotomy areas. These can both be huge. A highly respected surgeon now using in the prostatectomy surgery..could become standard procedure. If candyman is lucky, MDXG products may one day be used in his future lobotomy.
June 3, 2014
MiMedx says 'comfortable' with 'Top 3' analysts' FY15 revenue range
MiMedx stated in slides for its presentation at the Jefferies Global Healthcare Conference that the company is "comfortable" with the "Top 3" analysts' FY15 revenue projection range of $145.5M-$156.8M. FY15 revenue consensus $150.94M, according to First Call. The company noted a fourth analyst projection of FY15 revenue of $133M, stating that the "low end projection overstates impact of 'pass through' status while ignoring other growth catalysts and product competitive advantages." :theflyonthewall
That is correct. A stock buy back authorization by any company is just that, an authorization by the board authorizing management to buy stock. Many companies never end up buying a share. I have worked at large public companies for nearly 25 years. I am generally NOT a fan of stock buy backs. I think it made some sense in this case to help thwart off short
attempts but other than that, I'm not a fan. They do little to enhance long term value of share price. And for the record pacorabon69, I am not in this stock as heavy as I am to cheerlead but to make money, and a lot of it. I already have but there is much more to come in my view. If you consider that cheerleading, so be it. You can always put me on ignore
I defy anyone to find a senior management team at ANY public company that is more confident about where their company is headed than the team at MiMedx.
Still a very small portion of revenue. Keep in mind, there is NO ongoing sales effort on the injectable...just taking orders coming in
I am not suggesting that. I happen to agree with the company and the company's outside legal counsel that a license should not be required. That being said, I do not think the company is going to battle the FDA on this and will go through the BLA process. In my opinion, the FDA will allow MDXG to continue to distribute Amniofix during the BLA process given Amniofix's record of no adverse events. But, in the event that the FDA does not allow them to sell during the BLA process, MDXG will still have explosive growth and Amniofix likely would be ready to go in 2015
Correct alicecooper. The only question is whether MDXG can start selling the #$%$ out of Amniofix injectable this month or in 2015. For investors, it's just not a big deal.